Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc35118829    free
PDF from PMC    free
html from PMC    free
PDF vom PMID35118829  :  Publisher
PDF vom PMID35118829

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3 #MMPMID35118829
  • Henderson LA; Canna SW; Friedman KG; Gorelik M; Lapidus SK; Bassiri H; Behrens EM; Kernan KF; Schulert GS; Seo P; Son MBF; Tremoulet AH; VanderPluym C; Yeung RSM; Mudano AS; Turner AS; Karp DR; Mehta JJ
  • Arthritis Rheumatol 2022[Apr]; 74 (4): e1-e20 PMID35118829show ga
  • OBJECTIVE: To provide guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of SARS-CoV-2 infection. Recommendations are also provided for children with hyperinflammation during COVID-19, the acute, infectious phase of SARS-CoV-2 infection. METHODS: The Task Force is composed of 9 pediatric rheumatologists and 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician. Preliminary statements addressing clinical questions related to MIS-C and hyperinflammation in COVID-19 were developed based on evidence reports. Consensus was built through a modified Delphi process that involved anonymous voting and webinar discussion. A 9-point scale was used to determine the appropriateness of each statement (median scores of 1-3 for inappropriate, 4-6 for uncertain, and 7-9 for appropriate). Consensus was rated as low, moderate, or high based on dispersion of the votes. Approved guidance statements were those that were classified as appropriate with moderate or high levels of consensus, which were prespecified before voting. RESULTS: The guidance was approved in June 2020 and updated in November 2020 and October 2021, and consists of 41 final guidance statements accompanied by flow diagrams depicting the diagnostic pathway for MIS-C and recommendations for initial immunomodulatory treatment of MIS-C. CONCLUSION: Our understanding of SARS-CoV-2-related syndromes in the pediatric population continues to evolve. This guidance document reflects currently available evidence coupled with expert opinion, and will be revised as further evidence becomes available.
  • |*COVID-19/complications[MESH]
  • |*Rheumatology[MESH]
  • |Adult[MESH]
  • |Child[MESH]
  • |Humans[MESH]
  • |SARS-CoV-2[MESH]
  • |Systemic Inflammatory Response Syndrome/therapy[MESH]
  • |United States[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    e1 4.74 2022